Top Page
Emyria Ltd
(Sydney:EMD)
Emyria Ltd (EMD) vs. iShares MSCI Australia ETF (EWA)
Emyria Ltd Business Overview & Revenue Model
Emyria Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.39M | 1.39M | 2.20M | 1.59M | 1.82M | 1.98M |
| Gross Profit | 24.48K | 24.48K | -167.55K | -3.32M | -4.41M | -1.58M |
| EBITDA | -2.39M | -2.39M | -13.03M | -6.69M | -8.03M | -4.49M |
| Net Income | -3.14M | -3.14M | -11.46M | -5.13M | -7.33M | -4.91M |
Balance Sheet | ||||||
| Total Assets | 6.62M | 6.62M | 5.43M | 10.16M | 8.25M | 9.06M |
| Cash, Cash Equivalents and Short-Term Investments | 3.57M | 3.57M | 1.57M | 2.73M | 3.88M | 6.53M |
| Total Debt | 613.50K | 613.50K | 1.72M | 1.27M | 632.70K | 949.70K |
| Total Liabilities | 1.31M | 1.31M | 3.00M | 3.37M | 1.93M | 1.88M |
| Stockholders Equity | 5.31M | 5.31M | 2.43M | 6.79M | 6.32M | 7.18M |
Cash Flow | ||||||
| Free Cash Flow | -2.72M | -2.72M | -4.44M | -7.01M | -7.46M | -4.60M |
| Operating Cash Flow | -2.70M | -2.70M | -4.28M | -3.77M | -5.43M | -3.94M |
| Investing Cash Flow | 81.07K | 81.07K | -1.38M | -3.23M | -2.03M | -661.39K |
| Financing Cash Flow | 4.63M | 4.63M | 4.50M | 5.86M | 4.81M | 7.44M |
Emyria Ltd Technical Analysis
Emyria Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$24.32M | -5.23 | -27.84% | ― | 6.77% | -8.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$46.78M | -8.29 | -81.30% | ― | -36.68% | 79.41% | |
48 Neutral | AU$22.32M | -12.37 | -17.05% | ― | 28.91% | -1050.00% | |
43 Neutral | AU$77.34M | -10.79 | ― | ― | ― | ― | |
42 Neutral | AU$53.30M | -5.84 | -8647.54% | ― | 25.98% | 22.10% |
Emyria Ltd Corporate Events
Emyria Ltd has applied to the ASX for quotation of 50,000 new fully paid ordinary shares under its ticker code EMD, following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities, effective 23 January 2026, marginally expands the company’s issued capital base and indicates ongoing utilisation of equity-based instruments by investors or holders, but the filing provides no further detail on use of funds, strategic rationale, or operational impact for shareholders.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has applied to the ASX for quotation of 158,972 new fully paid ordinary shares under its existing EMD ticker. The additional securities, issued on 19 January 2026 following the exercise or conversion of existing instruments, modestly expand the company’s listed share capital and may provide incremental funding flexibility and liquidity for shareholders without materially altering its capital structure.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Limited has disclosed a change in the interests of director Mohit Kaushal, who has converted 2,000,000 performance rights into 2,000,000 fully paid ordinary shares under the company’s Employee Securities Incentive Plan. The conversion, which involved no cash consideration, increases Kaushal’s direct holding in ordinary shares and reflects ongoing use of equity-based incentives to align executive interests with shareholders, without any indication of trading during a closed period or changes in contractual interests.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Limited has applied to the ASX for quotation of 2,000,000 new fully paid ordinary shares under code EMD, following the exercise or conversion of existing options or other convertible securities. The additional shares, issued on 9 January 2026, will expand the company’s quoted capital base, potentially improving liquidity in its stock and modestly strengthening its balance sheet, with implications for existing shareholders’ dilution and the company’s funding capacity.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Limited has applied to the ASX for quotation of 23,595 new ordinary fully paid shares under the code EMD, with an issue date of 9 January 2026. The additional securities, resulting from the exercise or conversion of existing options or other convertible securities, represent a modest capital expansion and incremental increase in Emyria’s free float, offering slightly enhanced liquidity for shareholders without materially altering the company’s capital structure.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has notified the ASX that a series of listed options (EMDAS), exercisable at $0.35 and due to expire on 22 November 2025, have lapsed. The lapse of 10,333,328 options, due to conditions not being satisfied, reduces the company’s pool of potential future equity from these instruments but does not affect its existing issued capital, providing investors with updated clarity on its capital structure.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Limited has issued 82,785 new fully paid ordinary shares at $0.05 per share following the exercise of an equal number of options exercisable at the same price before March 2027. The company has lodged a cleansing notice under section 708A(5)(e) of the Corporations Act, confirming the shares were issued without a prospectus and that it is in compliance with its continuous disclosure and reporting obligations, enabling the new shares to be traded immediately on the ASX.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has applied to the ASX for quotation of 82,785 new fully paid ordinary shares under the code EMD. The additional securities, issued following the exercise or conversion of existing options or other convertible instruments, will modestly increase the company’s free float and share capital, providing incremental flexibility for existing holders and marginally broadening its investor base.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has issued 10 million unlisted options exercisable at $0.12 each, expiring on 27 November 2027, as part of previously announced transactions. The options, which will not be quoted on the ASX, represent a fresh tranche of unquoted equity that may provide additional capital to the company if exercised, potentially affecting its capital structure and dilution profile for existing shareholders over the medium term.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria has secured its first Victorian Empax clinic at the Mornington Peninsula, marking a significant milestone in its East Coast expansion and national clinic platform development. This expansion demonstrates Emyria’s ability to deploy its Empax clinic model consistently across jurisdictions using a capital-light, hospital-integrated framework, and active reimbursement pathways, thereby reducing execution risks and supporting revenue growth as new sites come online.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has announced significant progress in its Perth Clinic network, anticipating increased reimbursed clinical activity in 2026. The company has expanded its clinical capacity, with new treatment rooms and increased therapist numbers, to meet growing demand. The Perth model is set to serve as a scalable template for national expansion, particularly on the East Coast. The company is also enhancing its operations in Brisbane, with the successful onboarding of new clinical teams and the completion of initial treatments, positioning itself for substantial clinical and operational growth throughout 2026.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has announced the application for the quotation of 76,443 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategic efforts to enhance its financial positioning and operational capabilities, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Limited has announced the issuance of 133,333,334 new fully paid ordinary shares at an issue price of $0.06 per share, raising $8 million before costs. This capital raise allows the shares to be traded immediately under the exemption of section 708A(5) of the Corporations Act 2001, enhancing liquidity and potentially impacting the company’s market position.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has announced the quotation of 217,725 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of November 28, 2025. This move is part of the company’s strategy to enhance its financial flexibility and operational capacity, potentially strengthening its position in the healthcare market and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Ltd has announced the quotation of 133,333,334 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code EMD, effective from November 28, 2025. This move follows previous transactions and is part of the company’s strategic efforts to enhance its market presence and liquidity, potentially impacting its operational dynamics and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
Emyria Limited has announced the issuance of 916,667 new fully paid ordinary shares at an issue price of $0.05 per share following the exercise of options. This issuance allows the shares to be traded immediately under the exemption provided by section 708A(5) of the Corporations Act 2001, indicating compliance with relevant legal provisions and facilitating liquidity for stakeholders.
Emyria Ltd has announced the quotation of 1,388,316 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of November 21, 2025. This development is part of the company’s strategy to enhance its market presence and potentially increase its capital base, which could have significant implications for its stakeholders and industry positioning.
Emyria Ltd has announced a proposed issue of securities, including 10 million unlisted options and over 133 million ordinary fully paid shares. This move is part of a placement or other type of issue, with the proposed issue date set for November 28, 2025. The issuance is expected to enhance the company’s capital structure, potentially impacting its market positioning and providing opportunities for growth and expansion.
Emyria Limited has announced a significant expansion of its national presence by exercising an option to establish its first Empax Clinic in Victoria, marking a major milestone in its East Coast expansion. The company has secured exclusive rights to roll out Empax clinics across Avive Health’s network, enhancing its ability to provide intensive mental-health services nationwide. This expansion is supported by a successful $8 million institutional placement, which will accelerate the development of new sites and expand the clinical workforce. Additionally, Emyria has commenced revenue generation at its Brisbane clinic and has received support from the Department of Veterans’ Affairs for medication-assisted therapy, establishing a dual reimbursement pathway with private insurers.
Emyria Ltd has announced the quotation of 730,114 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code EMD. This move is part of the company’s strategy to enhance its market presence and provide more liquidity for its shareholders, potentially impacting its operational capacity and investor relations positively.
Emyria Limited announced that all resolutions presented at their Annual General Meeting were successfully carried by a poll. The resolutions included matters such as the remuneration report, election of a director, and approval of a 10% placement facility, among others. This outcome reflects strong shareholder support and may positively impact the company’s governance and strategic initiatives.
Emyria Ltd has announced the quotation of 322,976 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of November 7, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives, potentially impacting its market positioning and providing new opportunities for stakeholders.
Emyria Ltd has announced the cessation of 300,000 securities due to the expiry of options that were not exercised or converted by November 1, 2025. This development may affect the company’s capital structure and could have implications for its stakeholders, as it reflects changes in the company’s financial instruments.
Emyria Limited has reported significant growth in revenue and operational expansion in its quarterly activity report for September 2025. The company has expanded its agreement with Medibank to include insurer-funded access to its mental health treatment programs for PTSD and TRD in both Perth and Brisbane. This expansion marks the first national rollout of insured mental health treatment programs in Australia, demonstrating strong insurer confidence in Emyria’s care model. The company has also increased its workforce and treatment capacity to support growing demand, with plans to commence patient dosing in Brisbane by late Q4 2025. Emyria’s strategic partnerships and scalable model position it as a leader in evidence-based mental health care, with ongoing commercial momentum and broader national rollout plans.